These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38419467)

  • 1. Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease.
    Izumihara R; Nomoto H; Kito K; Yamauchi Y; Omori K; Shibayama Y; Yanagiya S; Miya A; Kameda H; Cho KY; Nagai S; Sakuma I; Nakamura A; Atsumi T
    Diabetes Metab J; 2024 May; 48(3):473-481. PubMed ID: 38419467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
    Tanaka A; Nakamura T; Sato E; Chihara A; Node K
    CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
    Kito K; Nomoto H; Sakuma I; Nakamura A; Cho KY; Kameda H; Miya A; Omori K; Yanagiya S; Handa T; Taneda S; Takeuchi J; Nagai S; Yamashita K; Kurihara Y; Atsumi T; Miyoshi H;
    Diabetes Res Clin Pract; 2022 Oct; 192():110091. PubMed ID: 36174777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
    Iwasaki M; Suzuki H; Umezawa Y; Koshida T; Saito M; Fukuda H; Takahara H; Matsuzaki K; Suzuki Y
    Medicine (Baltimore); 2023 Feb; 102(7):e32818. PubMed ID: 36800602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
    Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
    Diabetes Care; 2018 Mar; 41(3):538-546. PubMed ID: 29298800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
    Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.
    Horinouchi Y; Murashima Y; Yamada Y; Yoshioka S; Fukushima K; Kure T; Sasaki N; Imanishi M; Fujino H; Tsuchiya K; Shinomiya K; Ikeda Y
    Life Sci; 2023 May; 321():121590. PubMed ID: 36940907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD).
    Seki M; Nakano T; Tanaka S; Matsukuma Y; Funakoshi K; Ohkuma T; Kitazono T
    Clin Exp Nephrol; 2023 Apr; 27(4):358-364. PubMed ID: 36738362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
    Fruchart JC; Hermans MP; Fruchart-Najib J
    Curr Atheroscler Rep; 2020 Jul; 22(8):43. PubMed ID: 32671476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis.
    Dohmen K; Onohara SY; Harada S
    Korean J Gastroenterol; 2021 Oct; 78(4):227-234. PubMed ID: 34697277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
    Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
    J Atheroscler Thromb; 2018 Jun; 25(6):521-538. PubMed ID: 29628483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
    Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia.
    Nishida M; Horio T; Fukuda Y; Hayakawa Y; Tateishi Y; Akai M; Emoto M; Hasegawa T; Imanishi M
    Int J Clin Pharmacol Ther; 2023 Oct; 61(10):437-444. PubMed ID: 37548458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.
    Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
    Diabetes Obes Metab; 2019 Jul; 21(7):1737-1744. PubMed ID: 30830727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
    Komiya I; Yamamoto A; Sunakawa S; Wakugami T
    Lipids Health Dis; 2021 Feb; 20(1):17. PubMed ID: 33610176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.
    Penno G; Solini A; Zoppini G; Fondelli C; Trevisan R; Vedovato M; Gruden G; Lamacchia O; Pontiroli AE; Arosio M; Orsi E; Pugliese G;
    PLoS One; 2015; 10(5):e0125512. PubMed ID: 25942403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome.
    Nakamura A; Kagaya Y; Saito H; Kanazawa M; Sato K; Miura M; Kondo M; Endo H
    Heart Vessels; 2024 Jun; 39(6):486-495. PubMed ID: 38393377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.